Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | CCR1 | P32246 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434662 | 0.89 | PLA2G10 (0.51) | PLA2G10ELANECCR1TP53GSR | |
| SCHEMBL5437758 | 0.89 | TP53 (0.58) | PLA2G10ELANECCR1TP53MEN1 | |
| SCHEMBL5438359 | 0.86 | ELANE (0.54) | PLA2G10ELANECCR1GSR | |
| SCHEMBL5451795 | 0.86 | GAA (0.50) | PLA2G10ELANETP53SMN1; SMN2MEN1 | |
| SCHEMBL5434616 | 0.85 | PLA2G10 (0.48) | PLA2G10ELANECCR1GSR | |
| SCHEMBL5442918 | 0.84 | LMNA (0.52) | PLA2G10ELANECCR1TP53 | |
| SCHEMBL5757948 | 0.83 | ELANE (0.65) | ELANECCR1TP53SMN1; SMN2MEN1 | |
| SCHEMBL5434666 | 0.83 | ELANE (0.55) | PLA2G10ELANECCR1SMN1; SMN2MEN1 | |
| SCHEMBL5442993 | 0.83 | TP53 (0.47) | PLA2G10ELANECCR1TP53ALDH1A1 | |
| SCHEMBL5441836 | 0.83 | ELANE (0.54) | PLA2G10ELANECCR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, MPO | PLA2G10 1148/4885ELANE 2/4885CCR1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.